Margit M. Janát-Amsbury, M.D., Ph.D.

Research Interests

  • Drug Delivery Systems
  • Nanotechnology
  • Ovarian Neoplasms
  • Personalized Health Care
  • Cancer Stem Cell Research
  • Animal Model Development
  • Gynecologic Oncology

Languages

  • Czech
  • Dutch
  • English
  • French
  • German
  • Spanish

Academic Information

  • Departments: Bioengineering - Adjunct Assistant Professor, Obstetrics/Gynecology - Research Assistant Professor, Pharmaceutics and Pharmaceutical Chemistry - Adjunct Assistant Professor
  • Divisions: Gynecologic Oncology
  • Cancer Center Programs: Experimental Therapeutics

Academic Office Information

  • (801) 213-2248
  • School of Medicine
    Department of Obstetrics and Gynecology
    30 N 1900 E, Room: 2A242
    Salt Lake City, UT 84132

Research Statement

My research focuses on the development and translation of new drug and gene carriers for clinical use in cancer therapy, with a particular interest in gynecological malignancies including breast cancer and tumor immunology. The translational focus is oriented to link specialties like Nanomedicine, Pharmaceutical Chemistry and Bioengineering to the field of Obstetrics and Gynecology with main interest for Gynecologic Oncology.

Academic Bio

MARGIT M. JANÁT-AMSBURY is holding a faculty appointment as Assistant Professor with the Division of Gynecologic Oncology in the Department of Gynecology and Obstetrics in the School of Medicine at the University of Utah. She is an investigator in the Huntsman Cancer Institute and a member of the Experimental Therapeutics program. Prof. Janát-Amsbury's research focuses on the development and translation of cutting edge stem cell knowledge and new drug and gene carriers for clinical use in cancer therapy, with a particular interest in gynecological malignancies including breast cancer and tumor immunology. The translational focus is oriented to link specialties like Nanomedicine, Pharmaceutical Chemistry and Bioengineering to the field of Obstetrics and Gynecology with main interest for Gynecologic Oncology.

Education History

Type School Degree
Professional Medical Baylor College of Medicine
Gynecologic Oncology
M.D., Ph.D.
Fellowship University of Maastricht, Academisch Ziekenhuis (AZM), Dept. of OB/Gyn
Obstetrics and Gynecology
Clinical Fellow
Research Fellow University of Utah, Department of Pharmaceutics and Pharmaceutical Chemistry, Biomedical Polymers
Pharmaceutical Chemistry, Drug- and Gene Delivery
Postdoctoral Research Fellow
Residency Universitat zu Köln, Department of Obstetrics and Gynecology
Obstetrics and Gynecology
Resident
Professional Medical Universitat zu Köln
Molecular Biology/Oncology
M.D., Ph.D.
Internship/Residency Mount Sinai School of Medicine
Medical Oncology
Intern/Resident
Internship/Residency Universitat zu Köln, Department of Visceral and Vascular Surgery
Surgery
Intern/Resident
Internship/Residency Universitat zu Köln, Department of Obstetrics and Gynecology
Obstetrics & Gynecology
Intern/Resident
Professional Medical Universitat zu Köln, Medical School
Medicine
M.D.

Global Impact

Education History

Type School Degree Country
Fellowship University of Maastricht, Academisch Ziekenhuis (AZM), Dept. of OB/Gyn
Obstetrics and Gynecology
Clinical Fellow Netherlands
Residency Universitat zu Köln, Department of Obstetrics and Gynecology
Obstetrics and Gynecology
Resident Germany
Professional Medical Universitat zu Köln
Molecular Biology/Oncology
M.D., Ph.D. Germany
Internship/Residency Universitat zu Köln, Department of Visceral and Vascular Surgery
Surgery
Intern/Resident Germany
Internship/Residency Universitat zu Köln, Department of Obstetrics and Gynecology
Obstetrics & Gynecology
Intern/Resident Germany
Professional Medical Universitat zu Köln, Medical School
Medicine
M.D. Germany

Selected Publications

Journal Article

  1. Combinatorial gene construct and non-viral delivery for anti-obesity in diet-induced obese mice.Park H, Cho S, Han YH, Janat-Amsbury MM, Boudina S, Bae YH (2015). Combinatorial gene construct and non-viral delivery for anti-obesity in diet-induced obese mice. J Control Release, 207, 154-62.
  2. Park H, Cho S, Han YH, Janat-Amsbury MM, Boudina S, Bae YH (2015 Mar 25). Combinatorial gene construct and non-viral delivery for anti-obesity in diet-induced obese mice. J Control Release, 25(207), 154-162.
  3. Yang CH, Almomen A, Wee YS, Jarboe EA, Peterson CM, Jant-Amsbury MM (2015 Mar 23). An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations. Cancer Med.
  4. Almomen A, Cho S, Yang CH, Li Z, Jarboe EA, Peterson CM, Huh KM, Jant-Amsbury MM (2015 Jan 22). Thermosensitive Progesterone Hydrogel: A Safe and Effective New Formulation for Vaginal Application. Pharm Res.
  5. Theisen ER, Gajiwala S, Bearss J, Sorna V, Sharma S, Janat-Amsbury M (10/9/2014). Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer, October(14), 752.
  6. Abood Okal, Karina Matissek, Stephan Matissek, Robert Price, Mohamed Salama, Margit Maria Jant-Amsbury, and Carol Lim (06/24/2014). Re-engineered p53 Activates Apoptosis In Vivo and Causes Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model. Gene Therapy (Basingstoke).
  7. Arauchi A, Yang CH, Cho S, Jarboe EA, Peterson CM, Bae YH, Okano T, Jant-Amsbury MM (2014 May 27). An Immunocompetent, Orthotopic Mouse Model of Epithelial Ovarian Cancer Utilizing Tissue Engineered Tumor Cell Sheets. Tissue Engineering. Part C, Methods.
  8. Cho S, Sun Y, Jarboe EA, Soisson AP, Dodson MK, Gaffney DK, Peterson CM, Jant-Amsbury MM (Dec 2013). Mucoadhesive hybrid gel improves intraperitoneal platinum delivery. Int J Pharm, 458(1), 148-155.
  9. Sadekar S, Linares O, Noh G, Hubbard D, Ray A, Jant-Amsbury M, Peterson CM, Facelli J, Ghandehari H (2013). COMPARATIVE PHARMACOKINETICS OF PAMAM-OH DENDRIMERS AND HPMA COPOLYMERS IN OVARIAN-TUMOR-BEARING MICE. Drug Deliv Transl Res, Jun; 1((3)3), 260-271.
  10. Cho SungPil, Jarboe, Kennedy, Soisson, Dodson, Sun, Janat-Amsbury MM (April 2013). Development and characterization of a syngeneic mouse ovarian cancer model. Anticancer Res, 33(4), 1317-1324.
  11. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.Zhang R, Luo K, Yang J, Sima M, Sun Y, Janat-Amsbury MM, Kopecek J (2013). Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. J Control Release, 166(1), 66-74.
  12. Preparation and characterization of glycol chitin as a new thermogelling polymer for biomedical applications.Li Z, Cho S, Kwon IC, Janat-Amsbury MM, Huh KM (2013). Preparation and characterization of glycol chitin as a new thermogelling polymer for biomedical applications. Carbohydr Polym, 92(2), 2267-75.
  13. Cho S, Sun Y, Soisson AP, Dodson MK, Peterson CM, Jarboe EA, Kennedy AM, Janat-Amsbury MM (2013). Characterizing a syngeneic orthotopic mouse ovarian cancer model system for the evaluation of novel drug delivery systems. Anticancer Res, Apr; 33(4), 1317-24.
  14. Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice.Sadekar S, Ray A, Janat-Amsbury M, Peterson CM, Ghandehari H (2011). Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules, 12(1), 88-96.
  15. Correction to Comparative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in Ovarian-Tumor-Bearing Mice.Sadekar S, Ray A, Janat-Amsbury M, Peterson CM, Ghandehari H (2011). Correction to Comparative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in Ovarian-Tumor-Bearing Mice. (Epub ahead of print) Biomacromol.
  16. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages.Arnida, Janat-Amsbury MM, Ray A, Peterson CM, Ghandehari H (2011). Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm, 77(3), 417-23.
  17. Montejo M, Werner TL, Gaffney D, Janat-Amsbury MM (Aug. 2009). Current challenges in clinical management of endometrial cancer. Adv Drug Deliv Rev, 61(10), 883-9.
  18. Hunn J, Dodson MK, Webb J, Soisson AP, Janat-Amsbury MM (Aug. 2009). Endometrial cancer - current state of the art therapies and unmet clinical needs: the role of surgery and preoperative radiographic assessment. Adv Drug Deliv Rev, 61(10), 871-82.
  19. The role of gene- and drug delivery in women's health--unmet clinical needs and future opportunities. Preface.Janat-Amsbury MM, Peterson CM, Kim SW (2009). The role of gene- and drug delivery in women's health--unmet clinical needs and future opportunities. Preface. Adv Drug Deliv Rev, 61(10), 767.
  20. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer.Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW (2006). Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res, 26(4B), 2785-9.
  21. Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer.Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW (2006). Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res, 26(5A), 3223-8.
  22. Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment.Janat-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M, Kim SW (2005). Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment. J Control Release, 101(1-3), 273-85.
  23. Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: degradation profiles and evidence of dysopsonization.Bikram M, Lee M, Chang CW, Janat-Amsbury MM, Kern SE, Kim SW (2005). Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: degradation profiles and evidence of dysopsonization. J Control Release, 103(1), 221-33.
  24. Furgeson DY, Yockman JW, Jant MM, Kim SW (2004). Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes. Mol Ther, 9(6), 837-45.
  25. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model.Janat-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M, Kim SW (2004). Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther, 9(6), 829-36.
  26. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat-Amsbury MM, Untch M, Konecny G, Bruckner HW, Cree IA (2003). ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res, 161, 221-30.

Review

  1. Drug delivery for in vitro fertilization: rationale, current strategies and challenges.Janat-Amsbury MM, Gupta KM, Kablitz CD, Peterson CM (2009). Drug delivery for in vitro fertilization: rationale, current strategies and challenges. [Review]. Advanced Drug Delivery Reviews, 61(10), 871-82.

Book Chapter

  1. Janat-Amsbury, MM, Bae YH (11/30/2013). Nanotechnology in Cancer. In Michelle A. Rudek, Cindy H. Chau, William D. Figg, Howard L. McLeod (Eds.), Handbook of Anticancer Pharmacokinetics and Pharamcodynamics (pp. 703-730). New York: Springer New York.

Abstract

  1. Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW (2004). Combination of local, non-viral IL-12 gene delivery and systemic paclitaxel treatment in a highly metastatic mouse mammary carcinoma [Abstract]. SGI, Houston, USA.

Newspaper

  1. Janat-Amsbury, MM, Alter O (04/14/2015). University of Utah's researchers’ mathematical models could provide better ovarian cancer treatment outcomes. Salt Lake Tribune.